Evidence map›Paper›PMID 36420058›Full record

ArticleOpen forum infectious diseases2022

A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.

Claudia Ramirez-Sanchez, Jade Kozuch, Mita M Shah, Jennifer Berumen, Kristin Mekeel, Gabriel Schnickel, Mahnaz Taremi, Eugene Golts, Kamyar Afshar, Eric Adler and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Claudia Ramirez-SanchezDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-9012-7827
Jade KozuchDepartment of Pharmacy, University of California San Diego, La Jolla, California, USA.
Mita M ShahDivision of Nephrology, University of California San Diego, La Jolla, California, USA.
Jennifer BerumenDivision of Transplant and Hepatobiliary Surgery, University of California San Diego, La Jolla, California, USA.
Kristin MekeelDivision of Transplant and Hepatobiliary Surgery, University of California San Diego, La Jolla, California, USA.
Gabriel SchnickelDivision of Transplant and Hepatobiliary Surgery, University of California San Diego, La Jolla, California, USA.
Mahnaz TaremiDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
Eugene GoltsDivision of Cardiothoracic Surgery, University of California San Diego, La Jolla, California, USA.
Kamyar AfsharDivision of Pulmonary and Critical Care, University of California San Diego, La Jolla, California, USA.
Eric AdlerDivision of Cardiology, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-4765-0188
Victor PretoriusDivision of Cardiothoracic Surgery, University of California San Diego, La Jolla, California, USA.
Saima AslamDivision of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
University of California San Diego · USUniversity of California System · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS T32 AI007036
6 · The paper itself

Abstract

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Indexed as

DAAdirect-acting antiviraldonor-derived infectionglecaprevir/pibrentasvirHCVprophylaxis

Identifiers

PMID36420058
PMCPMC9679803
OpenAlexW4307641904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.